Gopalakrishnan, Sathej <br/><br/>
Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.  [electronic resource] 

 -  Advances in therapy  04 2016 
 - 670-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1865-8652 
<br/><br/><label>Standard No.: </label>10.1007/s12325-016-0320-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anilides--administration & dosage<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Cyclopropanes<br/>Double-Blind Method<br/>Drug Monitoring--methods<br/>Drug Therapy, Combination--methods<br/>Female<br/>Genes, Viral<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Japan--epidemiology<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--administration & dosage<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Ritonavir--administration & dosage<br/>Sulfonamides<br/>Treatment Outcome<br/>Valine